Aug. 4 at 7:11 PM
$PFE
Q2 revenue reached
$15B and adjusted EPS hit
$0.77, beating estimates by 13%. Eliquis sales surged 21% to
$2.43B, while Padcev and other oncology products continued gaining momentum.
Pfizer raised 2026 revenue guidance to
$60.5B to
$62.5B and now targets
$9.7B in total cost savings by 2029. Add a
$0.43 quarterly dividend and major upside from its oncology and obesity pipelines.
New all time highs are coming much sooner than investors expect! 🐂🔥🚀